Factor | Survived group (n = 22) | Deceased group (n = 14) | P value |
---|---|---|---|
Male sex | 13 (59.1) | 13 (92.9) | 0.054 |
Age (years), mean ± SD | 9.2 ± 5.3 | 10.0 ± 5.7 | 0.663 |
Underlying disorders | 0.294 | ||
 Acute myeloid leukemia  Acute lymphoblastic leukemia  Severe aplastic anemia  Neuroblastoma  Lymphoma  Severe combined immune deficiency | 12 (54.5) 6 (27.3) 3 (13.6) 1 (4.5) 0 (0.0) 0 (0.0) | 3 (21.4) 6 (42.9) 2 (14.3) 1 (7.1) 1 (7.1) 1 (7.1) | |
Remission state of underlying malignancya | 0.199 | ||
 Complete remission  Non-complete remission | 7 (36.8) 12 (63.2) | 1 (9.1) 10 (90.9) | |
Administered therapy preceding bacteremia | 0.123 | ||
 Induction chemotherapy  Re-induction chemotherapy  Consolidation chemotherapy  Autologous hematopoietic cell transplantation  Allogeneic hematopoietic cell transplantation  Palliative chemotherapy  Noneb | 2 (9.1) 8 (36.4) 6 (27.3) 0 (0.0) 2 (9.1) 2 (9.1) 2 (9.1) | 0 (0.0) 5 (35.7) 0 (0.0) 1 (7.1) 2 (14.3) 5 (35.7) 1 (7.1) | |
Central venous catheter | 0.318 | ||
 Hickman catheter  Subcutaneously implanted chemoport  None | 17 (77.3) 3 (13.6) 2 (9.1) | 10 (71.4) 4 (28.6) 0 (0.0) | |
Polymicrobial infection | 4 (18.2) | 5 (35.7) | 0.267 |
Breakthrough infection | 2 (9.1) | 6 (42.9) | 0.036 |
Local infection | 15 (68.2) | 11 (78.6) | 0.706 |
 Gastrointestinal tract infection  Respiratory tract infection  Skin and soft tissue infection  Catheter site infection | 9 (40.9) 4 (18.2) 5 (22.7) 2 (9.1) | 6 (42.9) 7 (50.0) 2 (14.3) 0 (0.0) | 0.908 0.067 0.681 0.511 |
Empirical antibiotic therapy | 0.008 | ||
 Piperacillin/tazobactam with aminoglycoside  Meropenem  Cefepime  Cefepime with aminoglycoside  Meropenem with aminoglycoside | 13 (59.1) 4 (18.2) 3 (13.6) 2 (9.1) 0 (0.0) | 3 (21.4) 10 (71.4) 0 (0.0) 0 (0.0) 1 (7.1) | |
Empirical combination antibiotic therapy | 15 (68.2) | 4 (28.6) | 0.039 |
Appropriateness of empirical antibiotics | |||
 Overall  β-lactam agents | 21 (95.5) 16 (72.7) | 9 (64.3) 8 (57.1) | 0.024 0.471 |
Fever duration (days), median (range) | 2 (1–53) | 4 (1–14) | 0.713 |
Complications  Hypoxia  Shock  Mechanical ventilator care  Renal dysfunction  Hepatic dysfunction | 4 (18.2) 2 (9.1) 3 (13.6) 2 (9.1) 1 (4.5) 0 (0.0) | 13 (92.9) 12 (85.7) 10 (71.4) 6 (42.9) 7 (50.0) 4 (28.6) | <0.001 <0.001 <0.001 0.036 0.003 0.017 |
Multidrug-resistant strain infections | 4 (18.2) | 9 (64.3) | 0.005 |